Sign In
Last checked at 
10 Mar 2026 15:26
10 March 2026
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Block Listing Interim Review
Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:
Name of Company | Aptamer Group plc |
Name of Scheme | The Aptamer Group EMI Share Option Scheme |
Period of Return (from/to) | 26 August 2025 to 24 February 2026 |
Number and class of securities not issued at the start of the period under the scheme | 576,053 Ordinary Shares |
Number of securities issued under the scheme during the period | 0 |
Number of securities lapsed/waived under the scheme during the period | 6,000 |
Balance under the scheme of securities not yet issued at the end of the period | 570,053 Ordinary Shares |
Number and class of securities originally admitted and the date of admission | 2,063,200 Ordinary Shares on 25 February 2022 |
Name of contact and telephone number | Andrew Rapson +44 (0) 1904 217 404 |
- Ends -
For further information, please contact:
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer | +44 (0) 1904 217 404 |
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Dillon Wall | +44 (0) 20 3368 3550 |
Turner Pope Investments (TPI) Limited - Broker Andrew Thacker / Guy McDougall | +44 (0) 20 3657 0050 |
Northstar Communications Limited - Investor Relations Sarah Hollins | +44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/
Follow the stocks
